Patents by Inventor Ana Dinca

Ana Dinca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating and preventing cardiomyopathy with a fusion protein of tafazzin and a cellular permeability peptide
    Patent number: 10086040
    Abstract: Methods for treating patients having a cardiomyopathy are provided. Additionally, methods for prophylactically treating patients at risk of developing a cardiomyopathy are provided. Methods for treating patients having, or at risk of developing, a cardiomyopathy may comprise administering a fusion protein including a tafazzin peptide and a cellular permeability peptide to the patient. Further, the tafazzin peptide may be coupled to the cellular permeability peptide by a polypeptide linker.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 2, 2018
    Assignee: University of Washington
    Inventors: Michael T. Chin, Wei-Ming Chien, Ana Dinca
  • METHODS FOR TREATING AND PREVENTING CARDIOMYOPATHY
    Publication number: 20170360886
    Abstract: Methods for treating patients having a cardiomyopathy are provided. Additionally, methods for prophylactically treating patients at risk of developing a cardiomyopathy are provided. Methods for treating patients having, or at risk of developing, a cardiomyopathy may comprise administering a fusion protein including a tafazzin peptide and a cellular permeability peptide to the patient. Further, the tafazzin peptide may be coupled to the cellular permeability peptide by a polypeptide linker.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicant: University of Washington
    Inventors: Michael T. CHIN, Wei-Ming CHIEN, Ana DINCA
  • Modified tafazzin proteins and methods of making and using the same
    Patent number: 9550981
    Abstract: Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker. Methods of making and using the fusion proteins are also disclosed. For example, the disclosed fusion proteins may be used to treat a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency (e.g., Barth syndrome). Additionally, the disclosed fusion proteins may be used in prophylaxis against developing a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency in a patient at risk of developing such a disorder.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: January 24, 2017
    Assignee: University of Washington
    Inventors: Michael T. Chin, Wei-Ming Chien, Ana Dinca
  • MODIFIED TAFAZZIN PROTEINS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20150203827
    Abstract: Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker. Methods of making and using the fusion proteins are also disclosed. For example, the disclosed fusion proteins may be used to treat a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency (e.g., Barth syndrome). Additionally, the disclosed fusion proteins may be used in prophylaxis against developing a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency in a patient at risk of developing such a disorder.
    Type: Application
    Filed: January 22, 2015
    Publication date: July 23, 2015
    Applicant: University of Washington Center for Commercialization
    Inventors: Michael T. Chin, Wei-Ming Chien, Ana Dinca